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Abstract
Post-approval changes are inevitable and necessary throughout the lifecycle of
pharmaceutical products to implement new knowledge, maintain a state of control, and
drive continual improvement.
This One-Voice-of-Quality (1VQ) position paper is part of a series of industry case studies
intended to demonstrate the standard application of the principles outlined in the
publication “Effective Management of Post-Approval Changes in the Pharmaceutical Quality
System (PQS) - Through Enhanced Science and Risk-Based Approaches Industry; One-Voiceof-Quality (1VQ) Solutions” in PDA Journal of Pharmaceutical Science and Technology, 2020
[1].
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Furthermore, this 1VQ position paper provides a practical application of the concepts
described in ICH Q9, Quality Risk Management [2], ICH Q10, Pharmaceutical Quality System
[3], and ICH Q12, Technical and Regulatory Considerations for Pharmaceutical Product
Lifecycle Management [4] to changes to analytical equipment/instrumentation that are
deemed to be equivalent.
This paper describes changes to analytical equipment that are considered ‘like for like’ or
equivalent. The conclusion drawn from this case study is that such changes present a low
risk, and therefore can be downgraded from a prior-approval, and managed only within the
company’s PQS.
KEYWORDS
CMC, Chemistry Manufacturing and Control, Regulatory, Post-approval Change, PAC, ICH
Q9, Quality Risk Management, QRM, ICH Q10, Pharmaceutical Quality System, PQS, ICH
Q12, Lifecycle Management, Change Control, Regulatory Considerations, Regulatory
Flexibility, Science and Risk-based Approach, One-Voice-Of-Quality, Analytical
Equipment/Instrumentation

BACKGROUND AND CONTEXT
ICH Q10, Pharmaceutical Quality System, Annex 1 describes potential opportunities to
enhance science and risk-based regulatory approaches to PACs as follows: When a company
can “demonstrate effective PQS and product and process understanding” this is an
opportunity to “optimize science and risk-based PAC processes to maximize benefits from
innovation and continual improvement” [3]. Current regulatory mechanisms and guidance
for PACs do not consider the company’s latest product and process knowledge when
determining the type of filing required to implement the change. Further, the application of
ICH Q9, Quality Risk Management, or the effectiveness of the company’s PQS to manage
PACs is not considered during the assessment of individual PACs or during inspections.
Demonstrating a detailed understanding, effective implementation, and compliance with
ICH Q10, will allow companies to overcome barriers to continual improvement and
innovation. Additionally, it will help reduce drug shortages in the global environment by
allowing faster implementation of PACs and reducing the PAC burden on both industry and
regulators.
This specific example of changes to analytical equipment/instrumentation that are deemed
to be equivalent demonstrates the application of the principles outlined in ICH Q9, Q10,
Q12 irrespective of current national or regional reporting category, and concludes that such
2
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changes can be managed within the PQS only without any regulatory submissions. It is
acknowledged that different companies might be handling this example differently and may
not need to pursue a regulatory downgrade for this PAC. However, companies that file this
as a prior approval change, may use this position paper as a starting basis and modify scope
and relevant considerations for their specific need and in accordance with their company’s
PQS requirements.
This PAC example and the 1VQ work in general is sponsored by the Chief Quality Officer’s
from more than 20 pharmaceutical companies [5].
DESCRIPTION OF CURRENT STATE FOR MANAGING CHANGES TO ANALYTICAL
EQUIPMENT/INSTRUMENTATION
Changes to analytical equipment/instrumentation are needed for a variety of reasons, e.g.
the instrument is no longer supported by a vendor or the instrument is outdated and no
longer able to be fixed, replacement parts are unavailable, a newer or better replacement is
available, software has been updated etc.
For analytical methods, and associated equipment/instruments/parts, software names and
versions, specific equipment names, brand and model number etc. may be detailed along
with the associated operating parameters relevant for that equipment/instrument/part
within the registrations. Often an allowance is included for an ‘equivalent’
equipment/instrument/part in the registration which provides the appropriate regulatory
flexibility for these types of changes. However, there are instances, where the term
“equivalent’ may not be included and this often creates an unnecessary need for health
authority approvals for these registration changes. This in turn delays proactive and timely
implementation of necessary analytical instrumentation changes which can be managed
under a robust PQS. A consequence of such delays is unnecessary and avoidable method or
equipment failures, errors, deviations or out of specification investigations that can result in
testing and product release delays.
This position paper describes how ICH Q10 and Q12 can provide the basis for regulatory
relief for certain ‘like for like’ changes in analytical equipment/instrumentation that present
no risk to product quality and/or patient safety and minimal regulatory risk. In some cases,
these types of changes can improve reliability of product supply to the patient and product
3
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quality. e.g. increase data integrity and cyber security, better sensitivity of the method and
the reduction in human error.
SCOPE
The position paper applies science and risk-based concepts from ICH Q9, Q10 and Q12 to
the following types of analytical equipment changes so that such changes can be
implemented proactively utilizing the framework of an effective PQS, and without extensive
regulatory burden:
•

Retirement, de-commissioning or replacement of ‘like for like’

1

laboratory

equipment/ instruments (offline, at-line, in-line, laboratory computer) and parts.
Examples include change from one equipment model or equipment part to another
where the manufacturer will no longer be manufacturing that model or part.
•

Installation of new laboratory equipment/instruments or parts that are ‘like for like’
which includes the use of automation when there is no change in the fundamental
principle of manual vs. automation techniques (i.e. moving from a manual to
automated lab operation is considered a ‘like for like’ change where the automation
mimics the core manual process, there is no change in the fundamental controls in
executing a method, and equivalence has been demonstrated between the manual
and automated operation).

INDUSTRY

1VQ

POSTION

FOR

MANAGING

ANALYTICAL

CHANGES

TO

EQUIPMENT/INSTRUMENTATION
ICH Q12, Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle
Management provides regulatory flexibility in post-approval changes to the product or its
manufacturing process based on latest product and process knowledge, sound-scientific and
risk-based approaches [4].

The term ‘Like for like’ applies where its replacement, retirement or decommissioning does
not cause any change in analytical methodology, method principles, method parameters and
method validation as defined by ICH Q2(R1), analytical specifications, or system suitability,
and/or where full method re-validation is not required, and equivalency has been
demonstrated.
1
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Leveraging the principles in ICH Q9, Q10 and Q12, regulatory discretion will be used for ‘like
for like’ changes to analytical equipment/instrumentation, where the change can be
managed solely within the PQS as long as the change assessment and/or equivalency data
conclude that the change does not impact product quality and/or patient safety.
Instrumentation change types should be considered Non-Regulatory Impacting if there are
no changes in analytical methodology, method principles, method parameters and method
validation as defined by ICH Q2(R1), Validation of Analytical Procedures: Text and
Methodology [6], analytical specifications, or system suitability, and method re-validation is
not required.
The pharmaceutical industry’s position is that such changes should not need to be assessed
as regulatory impacting, simply because the M3 dossier has additional equipment details
(e.g. part numbers, brand name, model or version numbers), or has not specifically stated
an allowance for ‘equivalent’ equipment/instrumentation. There is no regulatory
requirement to register detailed instrument settings and operating information, model
number, instrument name, etc.; therefore, it is not considered appropriate to update the
dossier with similar detail. These details can be removed or revised to include the term
“equivalent” in future updates to the dossier.
This will facilitate timely upgrades and replacement of outdated or aging analytical
equipment, reducing related errors, issues, delays in testing and release of product
ultimately ensuring reliable supply. In addition, it will contribute towards meeting the ICH
Q10 objectives of achieving product realization, establishing and maintaining a state of
control, and continual improvement.
As part of a company’s change control process, a science and risk-based approach with
appropriate justification will be documented when evaluating changes in the analytical
instrumentation that are deemed to be ‘like for like’, regardless of the detailed equipment
information filed.
STANDARD RISK-BASED APPROACH
Figure 1 below [1] describes the risk-based approach for assessment of a PAC to ‘like for
like’ analytical equipment/instrumentation. Application of this risk-based assessment and
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supporting equivalency data, should demonstrate that at a minimum, the change does not
increase the risk to product quality, efficacy and/or patient safety.
Figure 1: Risk-based Assessment of PACs and Determination of Regulatory Reporting
Category

Step 1 – Change Proposal

PAC

Change Mgmt.(CM)
System

High Level Impact Assessment of Change
NO
• Is there a potential impact to Quality, Safety
Efficacy (QSE) ?
• What might go wrong that may affect
QSE?
• Is there a potential legal / regulatory impact ?1

No impact on QSE AND
no legal / regulatory impact

Q9,
Q12

Step 2 – Change Evaluation
YES or MAYBE

(likely impact to ECs)

Assessment of risks to QSE
(based on current knowledge & Control Strategy)

Q9

Risk Assessment of
Change
(QRM tool/extent may vary)
HIGH

Assignment of regulatory reporting category :
• What is the legal / regulatory impact (e.g. to ECs )?
• Document justification for proposed reporting category

Q12

High risk
Prior-Approval

Step 3 – Change Implementation

MODERATE / LOW

Low/Moderate risk
Notification1

No submission/reporting required
Document with rationale within the
CM system and implement change

Change Implementation plan
(including risk controls identified)

Q9
Step 4 – Change Review & Closure

Change Review & Closure
(incl. Risk Review & Change Effectiveness)

1

Q9, Q10

Ongoing
Review/Monitoring
June 2019

(through PQS post change closure)

per local regulations

When a ‘like for like’ PAC to analytical equipment/instrumentation is proposed and entered
into the change management system, the potential Quality, Safety Efficacy (QSE) and
legal/regulatory impact of the change should be considered including current control
strategies. The impact assessment indicates that
•

there is no change in analytical methodology, method principles, method
parameters and method validation as defined by ICH Q2 (R2), analytical
specifications, or system suitability

•

there is no need for method re-validation

•

there is no impact to product QSE

As the initial impact assessment concluded that there is no potential impact associated with
the change, no further quality risk assessment is required. There may be a change needed
to the specific equipment details in the dossier, but none of these impact product QSE.
Therefore, an update to the dossier can be bundled with a future change, and a filing does
6
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not need to be submitted solely for this analytical equipment change. Such a change along
with the supporting equivalency assessment and revisions to relevant procedures, can be
managed solely within the company’s PQS and implemented immediately without the need
for a regulatory submission. Change implementation, review and closure should be
performed according to the change management process. After implementation of the
change, any unintended consequences introduced as a result of the change should be
evaluated, documented and handled adequately through effectiveness verification
mechanisms.
DEMONSTRATING EFFECTIVE MANAGEMENT OF A ‘LIKE FOR LIKE’ ANALYTICAL
EQUIPMENT CHANGE WITHIN THE PQS
The following risk control elements have been considered and documented within the PQS
for ensuring effective management of a ‘like for like’ change to analytical
equipment/instrumentation:
•

No change in analytical methodology

•

No change in method principles and/or method parameters

•

No change in approved method validation and no need for method re-validation

•

No change in approved analytical specifications, or system suitability

•

IQ/OQ/PQ is adequately performed and documented

•

Equivalency between current and new equipment is demonstrated and documented

•

Relevant test and equipment (e.g. maintenance) procedures are revised for the new
analytical equipment as part of the change implementation.

The PIC/S Recommendation Paper on How to Evaluate/Demonstrate the Effectiveness of a
Pharmaceutical Quality System in relation to Risk-based Change Management” [7] provides
a practical checklist tool that can be used by the company to evaluate the effectiveness of
its risk-based change management process.
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CONCLUSION
This 1VQ position paper provides a standard and enhanced risk-based approach within the
framework of an effective PQS, that can be utilized by any company to gain regulatory
flexibility, reduce the burden and global complexity, and enable faster implementation of
‘like for like’ changes to analytical equipment/instrumentation, without increasing risk to
the patient and/or product quality, safety and efficacy. More specifically, no regulatory prior
approval will be pursued based on the premise that appropriate ‘analytical’ due diligence’
has been completed and documented in the PQS. This would include such elements such as
instrument appropriately IQ/OQ/PQ under the company’s PQS, use of the same technology
e.g. HPLC to HPLC, equivalent data generated during PQ, and that no revalidation or requalification of method is required.
The benefits of practical application of the principles of ICH Q9, Q10 and Q12 as described in
this document are:
1. Continual improvement with timely (weeks or months vs years) implementation of
many PACs
2. Enhancing product availability and mitigating potential drug shortages
3. Focusing regulatory resources on PACs that may have a potential to impact product
quality as it relates to safety and efficacy
4. Reducing the regulatory approval burden for medium and low risk changes
5. Faster implementation of analytical equipment upgrades
About One-Voice-Of-Quality
Many post-approval changes require regulatory agency approval by individual countries
before implementation. Because of the global regulatory complexity, individual postapproval changes (PACs) usually take years for full worldwide approval even when they
reduce patient risk, improve compliance, or enhance the manufacturing process or test
methods.
Senior Quality leaders (Chief Quality Officers and Heads of Quality) from more than 20
global pharmaceutical companies are speaking with “One-Voice-Of-Quality” (1VQ) to
advocate for an effective management of specific PACs that currently are handled as a priorapproval change in some countries, but where a standard science and risk-based approach
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concludes that these should be downgraded to a notification or handled only in the
Pharmaceutical Quality System (PQS). This benefit would be a reduction of the
implementation timeline from years to months with no increased risk to patient safety.
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